Karamanoğlu Mehmetbey University
Karaman, Central, 695002, Turkey (Türkiye)
NCT Number: NCT07056231
Background: Sitting volleyball is a sport that relies primarily on upper body strength and anaerobic capacity. In critical in-game skills such as serve and spike, factors such as speed-endurance time and impact power play a decisive role in performance. There are limited studies in the literature examining the effects of low-dose caffeine consumption on these skills. The effects of ergogenic supplements in Paralympic sports have not been sufficiently investigated, and the potential benefits of caffeine on serve and spike performance in sitting volleyball players remain unclear. Purpose: The main purpose of this research was to determine the effects of low-dose caffeine (3 mg/kg) consumption on the serve speed, spike speed and Speed-Endurance performances of elite-level sitting volleyball players. Method: The study was designed using a randomized, double-blind, balanced, and crossover experimental design. 13 elite male athletes from the 2024 Paravolley European Champion Sitting Volleyball Men's National Team participated in the study. Participants were evaluated for serve speed, spike speed, and speed-endurance performances in both 3 mg/kg caffeine (CAF) and placebo (PLA) conditions.
Looking for future studies?
Notify Me18 year–35 year
Male
Interventional
Not applicable
Karaman, Central, 695002, Turkey (Türkiye)
This study aimed to investigate the effects of low-dose caffeine ingestion on key performance parameters in elite-level sitting volleyball athletes. Sitting volleyball is a Paralympic sport that relies heavily on upper body explosive strength and short-term anaerobic power. While caffeine is a well-known ergogenic aid in able-bodied sports, its role in Paralympic contexts remains underexplored. Using a randomized, double-blind, placebo-controlled crossover design, the effects of 3 mg/kg caffeine consumption were assessed in 13 elite male sitting volleyball players. Each participant completed performance assessments under both caffeine and placebo conditions. The primary goal was to examine whether caffeine intake would enhance serve speed, spike speed, and repeated sprint ability. The study provides new insights into the acute ergogenic effects of caffeine in Paralympic team sport athletes, highlighting its selective benefit on explosive upper-body tasks such as serving.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
A single oral dose of 3 mg of caffeine per kilogram of body weight form approximately 60 minutes before performance testing. Supplied by Oxford Vitality, ISO-certified.
polydextrose used as Placebo
Time frame: After 60 minutes ingestion of the supplement on test day (CAF and PLA)
Serve speed will be assessed using a calibrated radar device to record peak velocity of each participant's volleyball serve.
Time frame: After 60 minutes ingestion of the supplement on test day (CAF and PLA)
Maximum spike speed will be measured in kilometers per hour (km/h) using a radar gun during a standardized spike task conducted after supplementation in each condition.
Time frame: After 60 minutes ingestion of the supplement on test day (CAF and PLA)
The number of maximal shuttle runs completed in a repeated sprint ability (RSA) test protocol will be recorded to assess speed-endurance capacity.
Ulaç Can YILDIRIM
Other
The Effect of Low Dose Caffeine on Serve Speed, Spike Speed, and Speed-Endurance in Elite Sitting Volleyball Players: A Randomized Double-Blind Crossover Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07711665
Caffeine, Placebo - Control
Alcalá de Henares, Madrid, Spain
View Trial DetailsNCT07711652
Caffeine, Placebo
Alcalá de Henares, Madrid, Spain
View Trial DetailsNCT07333443
Caffeine, Climbing
Alcalá de Henares, Madrid, Spain
View Trial DetailsNCT07386899
Caffeine
Izmir, Bornova, Turkey (Türkiye)
View Trial Details